Related Experiment Video
Updated: Oct 5, 2025

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
Published on: November 29, 2024
COVID-19 outcomes in patients with antiphospholipid syndrome: a retrospective cohort study
Background:
Aim of this study is to investigate COVID-19 outcomes in patients with antiphospholipid syndrome (APS).
Methods:
A retrospective cohort was formed from APS patients. Patients were screened for a record of positive SARS-CoV 2 PCR. In PCR‑positive patients, clinical data and information regarding COVID-19 outcomes were collected from medical records.
Results:
A positive PCR test was detected in 9/53 APS patients, while 66.7 %, 33.3 % and 11.1 % of APS patients with COVID-19 were under hydroxychloroquine, LMWH or warfarin, and acetylsalicylic acid, respectively. There were 3/9 patients found to be hospitalized and one died. No new thrombotic event was reported in any of the patients during COVID-19 infection.
Conclusion:
Baseline use of hydroxychloroquine, antiaggregants and anticoagulants may be associated with an absence of new thrombotic event (Tab. 2, Ref. 33).
Related Concept Videos
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Peripheral Artery Disease I: Introduction
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

